您的当前位置:首页 > 行业数据 > 全球已布局PD(L)1*VEGF双抗的MNC将双抗联用ADC的临床及计划汇总
图片属性
图片格式:PNG 图片大小:225KB 图片尺寸:2302*594
同报告图片
 / 4
全球已布局PD(L)1*VEGF双抗的MNC将双抗联用ADC的临床及计划汇总_第1页
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
全球已布局PD(L)1*VEGF双抗的MNC将双抗联用ADC的临床及计划汇总_第2页
全球已布局PD(L)1*VEGF双抗的MNC将双抗联用ADC的临床及计划汇总_第3页
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
全球已布局PD(L)1*VEGF双抗的MNC将双抗联用ADC的临床及计划汇总_第4页
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
全球已布局PD(L)1*VEGF双抗的MNC将双抗联用ADC的临床及计划汇总_第5页
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
所属报告: 荣昌生物(688331)-A股公司研究报告:2026年展望:加入全球肿瘤一线竞争-260312(17页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠